Buy or sell Proclara Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Proclara Biosciences Stock

Proclara is pioneering a new approach to treating neurodegenerative diseases.

About Proclara Biosciences Stock

NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Funding History

March 2008$7.0M
March 2011$12.4M
March 2012$9.0M
May 2013$6.4M
March 2014$17.0M
January 2015$10.0M
September 2016$47.0M
November 2018$6.9M

Management

Member of the Board of Directors

Vicki Sato

Scientific Advisory Board

Cynthia Lemere

Co-founder and Scientific Advisor

Beka Solomon

Scientific Advisors

Paul Aisen

Scientific Advisory Board

Greg Petsko

SVP Preclinical Research and Development

Kimberley Gannon

Clinical Development Leader

Michael Grundman

Board of Directors

Paul D. Goldenheim

VP Regulatory and Compliance

Roxanne Bales

Board of Directors

Kenneth Buckfire

Scientific Advisory Board

Andres Lozano

Member of the Scientific Advisory Board

David Holtzman

Scientific Advisor

David Hafler

Board of Directors

Saira Ramasastry

Board of Directors

Nico Dosenbach

Board of Directors

John F. Dee

Board of Directors

Peter Smedvig

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo